Ogivri 150 mg powder for concentrate for solution for infusion

DRUG2 trials

Sponsors

Fondazione IRCCS Istituto Nazionale Dei Tumori, Institut Curie

Conditions

Endometrial cancerHER3-mutant and HER2-not amplified metastatic breast cancer

Phase 2

"H3RAKLES": Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer

Not yet recruitingCTIS2024-519624-24-00

Institut CurieHER3-mutant and HER2-not amplified metastatic breast cancer

Target: 20Updated: 2025-09-11

Phase 4

Akynzeo as antiemetic treatment in patients with endometrial cancer treated with taxane - platinum combination chemotherapy. NOEME study.

RecruitingCTIS2023-504150-35-00

Fondazione IRCCS Istituto Nazionale Dei TumoriEndometrial cancer

Start: 2024-02-21Target: 84Updated: 2025-12-01